Clinical Trials in Santiago Compostela, A Coruna
17 recruiting
Showing 1–17 of 17 trials
Recruiting
Phase 1Phase 2
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals188 enrolled30 locationsNCT07206056
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled492 locationsNCT07517263
Recruiting
Phase 3
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Generalized Myasthenia Gravis
Novartis Pharmaceuticals146 enrolled112 locationsNCT06517758
Recruiting
Phase 1
An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Novartis Pharmaceuticals57 enrolled14 locationsNCT07029555
Recruiting
Phase 1Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals232 enrolled85 locationsNCT06649110
Recruiting
Phase 3
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals50 enrolled31 locationsNCT05935215
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Acute Coronary Syndrome
Novartis Pharmaceuticals300 enrolled58 locationsNCT07102628
Recruiting
Phase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled92 locationsNCT06813911
Recruiting
Phase 1
An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
Systemic Lupus Erythematosus (SLE)
Novartis Pharmaceuticals54 enrolled13 locationsNCT06335979
Recruiting
Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Lupus Nephritis
Novartis Pharmaceuticals462 enrolled188 locationsNCT05126277
Recruiting
Phase 3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Novartis Pharmaceuticals550 enrolled127 locationsNCT06133972
Recruiting
Phase 4
Secukinumab Open Label Roll-over Extension Protocol
Autoimmunity, Inflammation
Novartis Pharmaceuticals1,000 enrolled167 locationsNCT04638647
Recruiting
Phase 4
Asciminib Roll-over Study
Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals347 enrolled84 locationsNCT04877522
Recruiting
Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Lupus Erythematosus, SystemicLupus Nephritis
Novartis Pharmaceuticals179 enrolled93 locationsNCT06581198
Recruiting
Phase 2
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Scleroderma, Diffuse
Novartis Pharmaceuticals96 enrolled80 locationsNCT06655896
Recruiting
Phase 2
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Idiopathic Inflammatory Myopathies
Novartis Pharmaceuticals123 enrolled55 locationsNCT06665256
Recruiting
Phase 1
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals106 enrolled21 locationsNCT06531499